Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform.
Glyphic Biotechnologies has raised $38.0M in total funding. The most recent round was Series A. The last funding was announced in September 2025.
Glyphic Biotechnologies's investors include Gaingels, Wing Venture Capital, Cantos, Artis Ventures, Qiagen.
Glyphic Biotechnologies is headquartered in New York, United States.
Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform.
Glyphic Biotechnologies is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Glyphic Biotechnologies — Funding & Investors." VCBacked, September 26, 2025, https://www.vcbacked.co/company/glyphic-biotechnologies. Accessed July 19, 2026.
VCBacked. (2025). Glyphic Biotechnologies — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/glyphic-biotechnologies
{{cite web |title=Glyphic Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/glyphic-biotechnologies |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated